ArticleBreast cancer research : BCR2025
APOBEC3B protein expression associates with poor prognosis for breast cancer patients with ER-positive disease.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Full-length structure of the anti-viral and pro-tumor DNA deaminase APOBEC3B.bioRxiv : the preprint server for biology · 2026Article
- Differential effects on tumor progression by APOBEC3A, APOBEC3B, and APOBEC3H Haplotype I in a breast cancer mouse xenograft model.Frontiers in genetics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
APOBEC enzymes, including APOBEC3B (A3B), have been linked to recurrent mutational patterns in breast cancers (BC). Currently, there is considerable level of evidence that A3B mRNA expression is associated with poor prognosis in ER-positive BC. Since the clinical relevance of A3B at the protein level has not been well studied, we evaluated A3B protein expression by immunohistochemistry on tumor tissue microarrays. Samples from 646 invasive, non-metastatic primary ER-positive BC patients who did not receive any systemic endocrine therapy as standard of care treatment, allowed us to study the pure prognostic impact of A3B protein expression on disease-free survival (DFS), metastatic disease-free survival (MFS), breast cancer specific-survival (BCSS), and overall survival (OS). Furthermore, 220 tumor specimens from BC patients who relapsed and did receive tamoxifen as first-line palliative treatment were included to study the association of A3B protein expression and progression free survival (PFS). Cox regression models were used to determine the impact of A3B protein expression on prognosis and PFS. We found that A3B expression associates with larger and higher grade tumors. Furthermore, univariable analyses showed that high A3B expression was associates with a shorter DFS (HR = 1.68; 95%CI = 1.31–2.14), MFS (HR = 1.93; 95%CI = 1.45–2.56), BCSS (HR = 2.72; 95%CI = 1.89–3.90), and OS (HR = 1.89; 95%CI = 1.40–2.56). Also, a shorter PFS (HR = 1.41; 95%CI = 1.03–1.92) was found. After adjustment for confounders, the observed associations remained significant. To conclude, in ER-positive BC, A3B protein expression is a marker for poor disease outcome and for rapid progression during endocrine treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.